13 Valent Pneumococcal Conjugate Vaccine - Follow-on Study

Sponsor

University of Oxford (Other)

Overall Status

Completed

CT.gov ID

NCT01095471

Collaborator

University of Bristol (Other), University of Southampton (Other), University of London (Other)

100

Enrollment

Locations

Arms

Duration (Months)

Patients Per Site

2.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a follow-on, multi-centre, open-label, clinical trial. The purpose of this trial is to investigate the concentrations of serotype-specific antibodies to IgG included in PCV13 in children who have received either the PCV7 or PCV13 primary immunisation at 2, 4 and 12 months of age. We intend to recruit all interested participants who completed the Wyeth-sponsored PCV13 infant trial study (6096A1-007) at selected study sites (i.e. those that recruited the majority of the children in the original study). The study will start in March 2010, at which time the eldest participants in the 6096A1-007 study will be approximately 42 months of age. There will be two visits per participant, 1 month apart from each other. At visit one, all participants will have a blood test and receive a dose of PCV13. At visit 2, all participants will have a blood test and will be offered the remaining pre-school booster vaccinations unless they have already received them.

Condition or Disease	Intervention/Treatment	Phase
Pneumococcal Disease	Biological: PCV13	Phase 4

Study Design

Study Type:

Interventional

Anticipated Enrollment :

100 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

A follow-on, Multi-centre, Open-label, Clinical, Phase 4 Trial to Investigate the Persistence of Serotype-specific Antibodies at 40 Months of Age in Children Who Have Received Either the 7-valent or the 13-valent Pneumococcal Conjugate Vaccine at 2, 4 and 12 Months of Age and Assessing the Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Booster Dose Given at 40 Months of Age

Study Start Date :

Apr 1, 2010

Actual Primary Completion Date :

Dec 1, 2010

Actual Study Completion Date :

Mar 1, 2011

Arms and Interventions

Arm	Intervention/Treatment
Experimental: PCV13 Initial vaccination with PCV13	Biological: PCV13 Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age. Other Names: 13-valent pneumococcal conjugate vaccine
Experimental: PCV7 Initial intervention with PCV7	Biological: PCV13 Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age. Other Names: 13-valent pneumococcal conjugate vaccine

Arm

Intervention/Treatment

Experimental: PCV13

Initial vaccination with PCV13

Biological: PCV13

Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.

Other Names:

13-valent pneumococcal conjugate vaccine

Experimental: PCV7

Initial intervention with PCV7

Biological: PCV13

Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.

Other Names:

13-valent pneumococcal conjugate vaccine

Outcome Measures

Primary Outcome Measures

To assess the effectiveness of PCV13 booster vaccinations [1 month]
To assess the proportion of participants, immunised with the 13-valent pneumococcal conjugate vaccine (PCV13) at 2, 4 and 12 months of age, who have IgG concentrations ≥ 0.35mcg/ml for PCV13 serotypes at the time when preschool booster vaccinations are due (at 40 months of age).

Secondary Outcome Measures

To assess IgG concentrations for PCV13 serotypes in children immunised with PCV7 and PCV13 [1 month]
To assess the proportion of participants, immunised with the 7-valent pneumococcal conjugate vaccine (PCV7) at 2, 4 and 12 months of age, who have IgG concentrations ≥ 0.35mcg/ml for PCV13 serotypes at the time when preschool booster vaccinations are due (at 40 months of age) and comparing these to the proportion of participants achieving this threshold after infant immunisation with PCV 13.
Compare PCV13 serotype-specific IgG geometric mean concentrations, opsonophagocytic activity geometric mean titres & the proportion of participants with PCV13 serotype-specific OPA titres ≥ 1:8 (at 40 months) when immunised in infancy with PCV7 or PCV13. [1 month]
Compare PCV serotype-specific IgG GMCs, OPA GMTs & proportion of participants with IgG concs ≥ 0.35mcg/ml & OPA titres ≥ 1:8 one month after booster dose of PCV13 at 40 months in children previously immunised with PCV7 & PCV13 at 2,4 & 12 months. [1 month]
To determine reactogenicity of the pre-school PCV13 booster in terms of rates of local and systemic reactions following vaccination. [1 month]
Investigate influence of genetic polymorphisms on the above immunological markers following infant immunisation with PCV7/PCV13 & following booster dose of PCV13 at 40 months & on the nature of adverse reactions observed after booster. [1 month]
Measure pneumococcal serotype-specific memory B cells frequencies before & 1 month after PCV13 dose (40 months) in subset previously immunised with PCV7/PCV13 at 2,4 & 12 months (serotype studies to include 4,14,23F (present in PCV7) & 1,3,19A). [1 month]

Eligibility Criteria

Criteria

Ages Eligible for Study:

39 Months to 46 Months

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Participant completed the Wyeth-sponsored PCV13 infant trial study (6096A1-007) at one of the study sites participating in this follow-on study.
Aged 39-46 months (inclusive) at time of enrolment.
Available for entire study period and whose parent/legal guardian can be reached by telephone.
Healthy children as determined by medical history, physical examination, done by a study nurse (and/or study doctor if required, depending on the medical history of the participant and physical assessment), and judgment of the investigator.
Parent/legal guardian must be able to complete all relevant study procedures during study participation.

Exclusion Criteria:

Has received further doses of pneumococcal vaccination with licensed or investigational pneumococcal vaccine other than those given as part of the Wyeth-sponsored PCV13 infant trial study (6096A1-007).
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae.
Major known congenital malformation or serious chronic disorder.
Significant neurologic disorder or history of seizures including febrile seizure, or significant stable or evolving disorders such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorder.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, synagisB).
Participation in another investigational study other than the Wyeth-sponsored PCV13 infant trial study (6096A1-007). Participation in purely observational studies is acceptable.
Child who is a direct descendant (child, grandchild) of the study site personnel.

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Bristol Children's Vaccine Centre, University of Bristol	Bristol	United Kingdom
2	St George's Vaccine Institute, University of London	London	United Kingdom
3	Oxford Vaccine Group, Dept Paediatrics, University of Oxford	Oxford	United Kingdom	OX3 7LJ
4	Wellcome Trust Clinical Research Facility, University of Southampton	Southampton	United Kingdom